Bastiaan Driehuys
Trial Pipeline
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
NCT07139899
129 Xenon Imaging in Patients Treated With Sotatercept
NCT06351345
Inhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia
NCT07037836
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
NCT06104228
129Xe MRI Cardiopulmonary
NCT06038630
Pulmonary Hypertension SOLAR
NCT04778046
Xenon MRI Pulm Hypertension
NCT04991454
Hyperpolarized 129Xe MRI for Imaging Pulmonary Function
NCT01280994
Oxidative Stress in Asthma
NCT04512547
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 8 |
Therapeutic Areas
What the Pipeline for Bastiaan Driehuys Shows
According to the ClinicalTrials.gov registry, Bastiaan Driehuys is linked to 37 US clinical trials across every stage of research activity. Of those, 36 studies are currently recruiting — about 97% of the sponsor's indexed portfolio — and 1 are already marked complete, representing roughly 3% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Bastiaan Driehuys reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 8 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Bastiaan Driehuys is Pulmonary Arterial Hypertension with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.